Mangrove Partners’s GSK GSK Stock Holding History

Mangrove Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-61,366	Closed	-$3.38M	–	466
2021 Q4	$3.38M	Buy	+61,366	New	+$3.19M	0.2%	173

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Mangrove Partners's GSK Position: Q1 2022 in Review

Mangrove Partners sold out of GSK (GSK) in Q1 2022, closing a stake of 61,366 shares — an estimated $3.38M sold.

Mangrove Partners first reported a position in GSK in Q4 2021 and held it in 1 quarter. The position peaked at $3.38M in Q4 2021. 929 funds tracked by Wall St. Rank hold GSK as of Q1 2022.

Mangrove Partners reported no remaining GSK position as of Q1 2022 after selling out during the quarter.
Mangrove Partners sold 61,366 GSK shares in Q1 2022, an estimated $3.38M.
Mangrove Partners first reported a position in GSK in Q4 2021 and held it in 1 quarter.
Mangrove Partners's GSK position peaked at $3.38M in Q4 2021.
929 funds tracked by Wall St. Rank held GSK as of Q1 2022.

Based on Mangrove Partners's 13F filing for Q1 2022, filed 16 May 2022.